Stay updated on KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.

Latest updates to the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedA new revision tag 'Revision: v3.5.3' was added and the previous tag 'Revision: v3.5.2' was removed, indicating the page was updated to version 3.5.3. This reflects a minor update to the page metadata.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision v3.5.2 was added and v3.5.0 was removed. This appears to be a metadata update with no changes to the study data, eligibility criteria, or results presented.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedRevision label updated to v3.5.0, replacing v3.4.3. No study details or user-facing content appear to be altered.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check78 days agoChange DetectedGastric cancer is added as a related MedlinePlus topic and the Genetic and Rare Diseases Information Center is referenced in the Resources section.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision: v3.4.2 was added to the site. The previous notice about government funding lapses and the earlier Revision: v3.4.1 text were removed.SummaryDifference0.4%

Stay in the know with updates to KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.